BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlycoVaxyn AG Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine


7/29/2013 9:17:48 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ZURICH-SCHLIEREN, Switzerland, July 29, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals (GSK) and Janssen Pharmaceuticals (JPI), GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that it has secured a Strategic Translation Award from the Wellcome Trust to finance its Shigella program.

The award will allow the Company to advance its Shigella bioconjugate vaccine by funding human safety and challenge studies in healthy adults to confirm the efficacy of a monovalent Shigella flexneri 2a vaccine, before testing a multivalent vaccine in field studies in children. Clinical trials are scheduled to start in 2014 in the USA.

Shigella is one of the main causes of a diarrheal disease that causes illness and death among young children in low-income countries. Various serotypes of this Gram-negative bacterium are responsible for the diarrhea and, with regional differences in serotype distribution, up to 6 serotypes need to be included in a vaccine to provide broad protection and prevent Shigellosis worldwide.

GlycoVaxyn's in vivo glycosylation technology enables the possibility to develop such a complex multivalent Shigella vaccine for the first time. Complexes of the antigenic surface polysaccharides and proteins can now be directly synthesized in genetically engineered bacterial cells. This multivalent Shigella bioconjugate vaccine can be manufactured at low costs, a distinct advantage compared to conjugate vaccines that are chemically produced.

"An estimated 1.1 million people die from Shigella infections each year, mostly children under the age of five living in low income countries," said Richard Seabrook, Ph.D., head of Business Development at the Wellcome Trust. "With rising antibiotic resistance limiting our treatment options, we urgently need an affordable vaccine that will provide broad protection against the many strains of Shigella bacteria that cause disease."

Dr Michael Wacker, chief scientific officer of GlycoVaxyn added, "We are very honored to work with this prestigious global charitable foundation and proud to contribute to the development of a vaccine that addresses a critical medical need among millions around the world. GlycoVaxyn has previously conducted a Phase 1 study in healthy volunteers on a single serotype Shigella conjugate vaccine. This collaboration will enable us to investigate a new vaccine against a different single serotype, moving this important program forward towards a broad acting vaccine that protects against multiple serotypes."

Gordon Dougan, Ph.D., member of GlycoVaxyn's Scientific Advisory Board and professor at the Wellcome Trust Sanger Institute in Cambridge commented, "GlycoVaxyn is using highly innovative technology to break open new fields in vaccinology. I am delighted to see them work together with the Wellcome Trust to apply this technology to vaccines for children suffering from dysentery."

About GlycoVaxyn AG

GlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary in vivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoprotein conjugates in a biological process that circumvents many of the challenges and uncertainties involved in currently used chemical methods. Besides Shigella, the portfolio includes preclinical programs targeting major infectious diseases such as Staphylococcus aureus and Streptococcus pneumoniae.GlycoVaxyn is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners and recently entered collaborations with GSK and JPI. For further information, visit www.glycovaxyn.com.

About The Wellcome Trust

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.

www.wellcome.ac.uk

Contacts:



Robert Flamm

GlycoVaxyn AG

Russo Partners, LLC

Tel: +41-44-733-8595

Tel: +1-212-845-4226

media@glycovaxyn.com

robert.flamm@russopartnersllc.com

SOURCE GlycoVaxyn AG



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES